Biggest News Aggregation in the World
📰 Iobt News

Page 2 - Iobt News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Iobt. Real-time updates on events, politics, business and more.

IO Biotech (NASDAQ:IOBT) Price Target Raised to $11.00

IO Biotech (NASDAQ:IOBT – Get Rating) had its target price hoisted by analysts at HC Wainwright from $10.00 to $11.00 in a research report issued on Friday, The Fly reports. HC Wainwright’s price target would indicate a potential upside of 431.35% from the stock’s previous close. Separately, Morgan Stanley reduced their price objective on shares […]
Amy Sullivan Io Biotech Company Profile Morgan Stanley Renaissance Technologies Io Biotech Inc Psagot Value Holdings Ltd
Source: wkrb13.com

Financial Contrast: IO Biotech (IOBT) and Its Competitors

IO Biotech (NASDAQ:IOBT – Get Rating) is one of 994 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare IO Biotech to similar businesses based on the strength of its risk, analyst recommendations, earnings, dividends, valuation, institutional ownership and profitability. Volatility & Risk IO Biotech has […]
Io Biotech Inc Get Rating Io Biotech Nasdaq Iobt Stock Comparison Stock Analysis
Source: wkrb13.com

IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Decline in Short Interest

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) saw a significant drop in short interest in May. As of May 31st, there was short interest totalling 2,900 shares, a drop of 44.2% from the May 15th total of 5,200 shares. Based on an average trading volume of 53,200 shares, the short-interest ratio is currently 0.1 days. […]
United States Geode Capital Management Io Biotech Inc Squarepoint Ops Io Biotech Company Profile Get Rating America Corp

IO Biotech (NASDAQ:IOBT) Downgraded by Zacks Investment Research to "Hold"

IO Biotech (NASDAQ:IOBT – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday, Zacks.com reports. According to Zacks, “IO Biotech Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel, immune-modulating cancer therapies based on its T-win(R) technology platform. IO […]
Io Biotech Inc Zacks Investment Research Norges Bank Samsara Biocapital Novo Holdings Get Rating

Jefferies Financial Group Weighs in on IO Biotech, Inc.'s Q2 2022 Earnings (NASDAQ:IOBT)

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) – Equities researchers at Jefferies Financial Group raised their Q2 2022 earnings estimates for shares of IO Biotech in a report issued on Monday, May 16th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will post earnings per share of ($0.40) for the quarter, up […]
United States Jefferies Financial Group Geode Capital Management Stifel Financial Corp Io Biotech Inc Zacks Investment Research

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

IO Biotech, Inc. (NASDAQ:IOBT) Expected to Announce Earnings of -$0.69 Per Share

Equities analysts predict that IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) will post earnings per share of ($0.69) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for IO Biotech’s earnings, with the lowest EPS estimate coming in at ($0.87) and the highest estimate coming in at ($0.50). The […]
United States Geode Capital Management Stifel Financial Corp Io Biotech Inc Virtu Financial Zacks Investment Research

IO Biotech, Inc. (NASDAQ:IOBT) Short Interest Update

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) saw a large decrease in short interest in the month of April. As of April 30th, there was short interest totalling 10,400 shares, a decrease of 24.6% from the April 15th total of 13,800 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average […]
United States Geode Capital Management Io Biotech Inc Stifel Financial Corp Virtu Financial Zacks Investment Research

IO Biotech, Inc. (NASDAQ:IOBT) Sees Significant Increase in Short Interest

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 13,800 shares, an increase of 68.3% from the March 31st total of 8,200 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average […]
United States Geode Capital Management Io Biotech Inc Zacks Investment Research America Corp Squarepoint Ops

Zacks: Brokerages Expect IO Biotech, Inc. (NASDAQ:IOBT) Will Announce Earnings of -$0.69 Per Share

Analysts expect IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) to report ($0.69) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for IO Biotech’s earnings, with estimates ranging from ($0.87) to ($0.50). The company is scheduled to report its next quarterly earnings report on Monday, January 1st. According […]
United States Geode Capital Management Stifel Financial Corp Io Biotech Inc Virtu Financial Zacks Investment Research

IO Biotech, Inc. (NASDAQ:IOBT) Sees Large Drop in Short Interest

IO Biotech, Inc. (NASDAQ:IOBT – Get Rating) saw a significant decline in short interest in the month of March. As of March 31st, there was short interest totalling 8,200 shares, a decline of 78.2% from the March 15th total of 37,700 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio […]
Io Biotech Inc Zacks Investment Research Millennium Management Samsara Biocapital Novo Holdings Get Rating

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science